Shoreline Biosciences Stock

shorelinebio.comHealthcareFounded: 2020Funding to Date: $186MM

Shoreline Biosciences is a biotechnology company focused on immunotherapies for patients who are ill. Their core focus is on induced Pluripotent Stem Cells (iPSCs) and Macrophages (iMACs) which aim to target tumor and cancer cells. Shoreline Biosciences was founded in 2020 by Dan Kaufman, Kleanthis Xanthopoulos Ph.D, and Steven Holtzman and is headquartered in San Diego, CA.

Register for Details

For more details on financing and valuation for Shoreline Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Shoreline Biosciences.

Register Today

Shoreline Biosciences investors also invested in these private companies

Team

Management Team

Vanessa Jacoby
Chief Financial Officer
Robert Hollingsworth Ph.D
Chief Scientific Officer
Scott Forrest Ph.D
Chief Business Officer
Mauro Avanzi
Chief Medical Officer
Chuck Calderaro III
Chief Technical Officer
Kleanthis Xanthopoulos Ph.D
Chief Executive Officer & Chairman

Board Members

Christopher Fuglesang Ph.D
Boxer Capital
Frank Yu
Ally Bridge Group
Simos Simeonidis Ph.D
Ally Bridge Group

Other companies like Shoreline Biosciences in the Healthcare sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$809.52MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$396.01MM
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$1.53B

News

Shoreline Biosciences has poached the leader of Pfizer's cancer vaccines unit, Robert Hollingsworth, Ph.D., to serve as chief scientific officer for the startup, which has recently beefed up its leadership, financing and partnerships.